Onconova Therapeutics (NASDAQ: ONTX) was reduced by Zacks  from a “buy” score to a “hold” ranking in a research note released to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on finding as well as developing small molecule drug prospects to treat cancer. The Company‘s products under various phases of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts also recently talked about the firm. Noble Financial editioned a “get” score and issued a $11.00 cost objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and set a “acquire” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating ordinary price of $2.90 and also a two-hundred day moving typical rate of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) profits per share for the quarter, covering experts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as an adverse web margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, contrasted to the consensus quote of $0.06 million. During the same quarter in the prior year, the firm posted ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will publish -1.18 EPS for the present year.

A variety of hedge funds have lately dealt shares of ONTX. GSA Resources Partners LLP purchased a new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Capital Management LP got a brand-new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP purchased a new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also other institutional capitalists own 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the identification as well as growth of oncology therapeutics. It focuses on finding and establishing small molecule medication prospects to deal with cancer cells. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a cost-free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

To find out more about research offerings from Zacks Investment Research, browse through Zacks.com.

This instantaneous news alert was generated by narrative science modern technology and also monetary data from Market in order to provide viewers with the fastest and also most accurate reporting. This tale was evaluated by Market’s content group before publication. 



Prior to you take into consideration Onconova Therapeutics, you’ll want to hear this.

Market keeps track of Wall Street’s premier as well as best carrying out research experts as well as the stocks they recommend to their customers every day. Market has actually determined the five stocks that top analysts are quietly whispering to their customers to get currently before the more comprehensive market catches on … and Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics presently has a “Buy” score among analysts, top-rated experts believe these five stocks are much better purchases.